CD38 and Miyoshi myopathy: Targeted therapies, represented by anti CD38 monoclonal antibodies (eg, daratumumab and isatuximab) and CAR-T therapies, have further improved the prognosis of MM patients, especially for those with relapsed/refractory MM (14–16).